EZH2 and diffuse large B-cell lymphoma: In patients with DLBCL, our IHC assay should be carried out alongside Sanger sequencing for EZH2. We propose that when both parameters are concordant, no further testing would be necessary: EZH2 mutant patients with mutant-like IHC methylation profiles would be recommended for EZH2 inhibitor treatment, whereas WT EZH2 patients with WT-like IHC methylation profiles would not.